Skip to main content

Prevalence and molecular epidemiology of acquired AmpC β-lactamases and carbapenemases in Enterobacteriaceae isolates from 35 hospitals in Spain

European Journal of Clinical Microbiology & Infectious Diseases volume 32, pages 253–259 (2013)Cite this article

An Erratum to this article was published on 09 October 2012

Abstract

The purpose of this investigation was to determine the prevalence of plasmid-mediated AmpC (pAmpC) and carbapenemases in Enterobacteriaceae collected from 35 hospitals in Spain and to establish their epidemiological relationships. We conducted a prospective multi-centre study on pAmpC- or carbapenemase-producing Enterobacteriaceae isolates from clinical samples collected from February to July 2009. The strains suspected to carry pAmpC were resistant or showed intermediate susceptibility to co-amoxiclav and second- or third-generation cephalosporins. Strains suspected to carry a carbapenemase were selected because they showed a minimum inhibitory concentration (MIC) to imipenem >1 mg/L. Polymerase chain reaction (PCR) and a sequencing strategy were used to characterise the enzymes. The clonal relationships between isolates was analysed by pulsed field gel electrophoresis (PFGE). Among 100,132 Enterobacteriaceae isolates collected, 1,654 were compatible with the production of pAmpC or carbapenemases. We found a prevalence of 0.64 % of pAmpC (n = 635) and 0.04 % of carbapenemases (n = 43). The most prevalent pAmpC enzymes were CMY-type (78.3 %), DHA-type (19.5 %), ACC-type (1.6 %) and FOX-type (0.6 %). The CMY-type was the most frequent in Escherichia coli and Proteus mirabilis species, whereas the DHA-type was mainly found in Klebsiella spp. The enzymes involved in carbapenem resistance were VIM-1, IMP-22 and the new IMP-28. Nine new bla genes were described: bla CMY-54, bla CMY-55, bla CMY-56, bla CMY-57, bla CMY-96, bla DHA-6, bla DHA-7, bla FOX-8 and bla IMP-28. The prevalence of pAmpC or carbapenemases found is not negligible. The CMY-types were the predominant pAmpC, whereas the VIM or IMP enzymes were the predominant carbapenemases. Furthermore, we observed a great genetic diversity among pAmpC-producing strains and a close clonal relationship between carbapenemase-producing strains.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

References

  1. Pérez-Pérez FJ, Hanson ND (2002) Detection of plasmid-mediated AmpC β-lactamase genes in clinical isolates by using multiplex PCR. J Clin Microbiol 40:2153–2162

    PubMed  Article  Google Scholar 

  2. Mata C, Miró E, Rivera A et al (2010) Prevalence of acquired AmpC β-lactamases in Enterobacteriaceae lacking inducible chromosomal ampC genes at a Spanish hospital from 1999 to 2007. Clin Microbiol Infect 16:472–476

    PubMed  Article  CAS  Google Scholar 

  3. Navarro F, Pérez-Trallero E, Marimón JM et al (2001) CMY-2-producing Salmonella enterica, Klebsiella pneumoniae, Klebsiella oxytoca, Proteus mirabilis and Escherichia coli strains isolated in Spain (October 1999–December 2000). J Antimicrob Chemother 48:383–389

    PubMed  Article  CAS  Google Scholar 

  4. Yamasaki K, Komatsu M, Abe N et al (2010) Laboratory surveillance for prospective plasmid-mediated AmpC β-lactamases in the Kinki region of Japan. J Clin Microbiol 48:3267–3273

    PubMed  Article  CAS  Google Scholar 

  5. Song W, Kim JS, Kim HS et al (2006) Increasing trend in the prevalence of plasmid-mediated AmpC β-lactamases in Enterobacteriaceae lacking chromosomal ampC gene at a Korean university hospital from 2002 to 2004. Diagn Microbiol Infect Dis 55:219–224

    PubMed  Article  CAS  Google Scholar 

  6. Empel J, Baraniak A, Literacka E et al (2008) Molecular survey of β-lactamases conferring resistance to newer β-lactams in Enterobacteriaceae isolates from Polish hospitals. Antimicrob Agents Chemother 52:2449–2454

    PubMed  Article  CAS  Google Scholar 

  7. Miró E, Segura C, Navarro F et al (2010) Spread of plasmids containing the bla VIM-1 and bla CTX-M genes and the qnr determinant in Enterobacter cloacae, Klebsiella pneumoniae and Klebsiella oxytoca isolates. J Antimicrob Chemother 65:661–665

    PubMed  Article  Google Scholar 

  8. Oteo J, Hernández-Almaraz JL, Gil-Antón J et al (2010) Outbreak of VIM-1-carbapenemase-producing Enterobacter cloacae in a pediatric intensive care unit. Pediatr Infect Dis J 29:1144–1146

    PubMed  Article  Google Scholar 

  9. Conejo MC, Domínguez MC, López-Cerero L et al (2010) Isolation of multidrug-resistant Klebsiella oxytoca carrying bla IMP-8, associated with OXY hyperproduction, in the intensive care unit of a community hospital in Spain. J Antimicrob Chemother 65:1071–1073

    PubMed  Article  CAS  Google Scholar 

  10. Giakoupi P, Maltezou H, Polemis M et al; Greek System for the Surveillance of Antimicrobial Resistance (2009) KPC-2-producing Klebsiella pneumoniae infections in Greek hospitals are mainly due to a hyperepidemic clone. Euro Surveill 14. pii: 19218

  11. Cuzon G, Ouanich J, Gondret R et al (2011) Outbreak of OXA-48-positive carbapenem-resistant Klebsiella pneumoniae isolates in France. Antimicrob Agents Chemother 55:2420–2423

    PubMed  Article  CAS  Google Scholar 

  12. Struelens MJ, Monnet DL, Magiorakos AP et al; European NDM-1 Survey Participants (2010) New Delhi metallo-β-lactamase 1-producing Enterobacteriaceae: emergence and response in Europe. Euro Surveill 15. pii: 19716

  13. Miriagou V, Cornaglia G, Edelstein M et al (2010) Acquired carbapenemases in Gram-negative bacterial pathogens: detection and surveillance issues. Clin Microbiol Infect 16:112–22

    PubMed  Article  CAS  Google Scholar 

  14. Navarro F, Calvo J, Cantón R et al (2011) Detection of resistance phenotypes in gram-negative bacteria. Enferm Infecc Microbiol Clin 29:524–534

    PubMed  Article  Google Scholar 

  15. Walther-Rasmussen J, Høiby N (2007) Class A carbapenemases. J Antimicrob Chemother 60:470–482

    PubMed  Article  CAS  Google Scholar 

  16. Clinical and Laboratory Standards Institute (CLSI) (2005) Performance standards for antimicrobial susceptibility testing; fourteenth informational supplement, M100-S14. CLSI, Wayne, PA, USA

  17. Pasteran F, Mendez T, Guerriero L et al (2009) Sensitive screening tests for suspected class A carbapenemase production in species of Enterobacteriaceae. J Clin Microbiol 47:1631–1639

    PubMed  Article  CAS  Google Scholar 

  18. Dubois V, Poirel L, Marie C et al (2002) Molecular characterization of a novel class 1 integron containing bla GES-1 and a fused product of aac(3)-Ib/aac(6″)-Ib” gene cassettes in Pseudomonas aeruginosa. Antimicrob Agents Chemother 46:638–645

    PubMed  Article  CAS  Google Scholar 

  19. Yigit H, Queenan AM, Anderson GJ et al (2001) Novel carbapenem-hydrolyzing β-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob Agents Chemother 45:1151–1161

    PubMed  Article  CAS  Google Scholar 

  20. Poirel L, Magalhaes M, Lopes M et al (2004) Molecular analysis of metallo-β-lactamase gene bla SPM-1-surrounding sequences from disseminated Pseudomonas aeruginosa isolates in Recife, Brazil. Antimicrob Agents Chemother 48:1406–1409

    PubMed  Article  CAS  Google Scholar 

  21. Poirel L, Lambert T, Türkoglü S et al (2001) Characterization of Class 1 integrons from Pseudomonas aeruginosa that contain the bla VIM-2 carbapenem-hydrolyzing β-lactamase gene and of two novel aminoglycoside resistance gene cassettes. Antimicrob Agents Chemother 45:546–552

    PubMed  Article  CAS  Google Scholar 

  22. Rodríguez-Baño J, Miró E, Villar M et al (2012) Colonisation and infection due to Enterobacteriaceae producing plasmid-mediated AmpC β-lactamases. J Infect 64:176–183

    PubMed  Article  Google Scholar 

  23. Oteo J, Navarro C, Cercenado E et al (2006) Spread of Escherichia coli strains with high-level cefotaxime and ceftazidime resistance between the community, long-term care facilities, and hospital institutions. J Clin Microbiol 44:2359–2366

    PubMed  Article  CAS  Google Scholar 

  24. Sabbuba NA, Mahenthiralingam E, Stickler DJ (2003) Molecular epidemiology of Proteus mirabilis infections of the catheterized urinary tract. J Clin Microbiol 41:4961–4965

    PubMed  Article  CAS  Google Scholar 

  25. Tenover FC, Arbeit RD, Goering RV et al (1995) Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol 33:2233–2239

    PubMed  CAS  Google Scholar 

  26. Ding H, Yang Y, Lu Q et al (2008) The prevalence of plasmid-mediated AmpC β-lactamases among clinical isolates of Escherichia coli and Klebsiella pneumoniae from five children’s hospitals in China. Eur J Clin Microbiol Infect Dis 27:915–921

    PubMed  Article  CAS  Google Scholar 

  27. Queenan AM, Bush K (2007) Carbapenemases: the versatile β-lactamases. Clin Microbiol Rev 20:440–458

    PubMed  Article  CAS  Google Scholar 

  28. Tórtola MT, Lavilla S, Miró E et al (2005) First detection of a carbapenem-hydrolyzing metalloenzyme in two Enterobacteriaceae isolates in Spain. Antimicrob Agents Chemother 49:3492–3494

    PubMed  Article  Google Scholar 

  29. Tato M, Coque TM, Ruíz-Garbajosa P et al (2007) Complex clonal and plasmid epidemiology in the first outbreak of Enterobacteriaceae infection involving VIM-1 metallo-β-lactamase in Spain: toward endemicity? Clin Infect Dis 45:1171–1178

    PubMed  Article  CAS  Google Scholar 

  30. Pérez-Llarena FJ, Fernández A, Zamorano L et al (2012) Characterization of a novel IMP-28 metallo-β-lactamase from a Spanish Klebsiella oxytoca clinical isolate. Antimicrob Agents Chemother 56:4540–4543

    PubMed  Article  Google Scholar 

  31. Gaibani P, Ambretti S, Berlingeri A et al (2011) Rapid increase of carbapenemase-producing Klebsiella pneumoniae strains in a large italian hospital: surveillance period 1 March–30 September 2010. Euro Surveill 16. pii: 19800

  32. Solé M, Pitart C, Roca I et al (2011) First description of an Escherichia coli strain producing NDM-1 carbapenemase in Spain. Antimicrob Agents Chemother 55:4402–4404

    PubMed  Article  Google Scholar 

  33. Pitart C, Solé M, Roca I et al (2011) First outbreak of a plasmid-mediated carbapenem-hydrolyzing OXA-48 β-lactamase in Klebsiella pneumoniae in Spain. Antimicrob Agents Chemother 55:4398–4401

    PubMed  Article  CAS  Google Scholar 

  34. Oteo J, Cercenado E, Cuevas O et al (2010) AmpC β-lactamases in Escherichia coli: emergence of CMY-2-producing virulent phylogroup D isolates belonging mainly to STs 57, 115, 354, 393, and 420, and phylogroup B2 isolates belonging to the international clone O25b-ST131. Diagn Microbiol Infect Dis 67:270–276

    PubMed  Article  CAS  Google Scholar 

  35. Naseer U, Haldorsen B, Simonsen GS et al (2010) Sporadic occurrence of CMY-2-producing multidrug-resistant Escherichia coli of ST-complexes 38 and 448, and ST131 in Norway. Clin Microbiol Infect 16:171–178

    PubMed  Article  CAS  Google Scholar 

  36. Empel J, Hrabák J, Kozińska A et al (2010) DHA-1-producing Klebsiella pneumoniae in a teaching hospital in the Czech Republic. Microb Drug Resist 16:291–295

    PubMed  Article  CAS  Google Scholar 

  37. Ohana S, Leflon V, Ronco E et al (2005) Spread of a Klebsiella pneumoniae strain producing a plasmid-mediated ACC-1 AmpC β-lactamase in a teaching hospital admitting disabled patients. Antimicrob Agents Chemother 49:2095–2097

    PubMed  Article  CAS  Google Scholar 

  38. Psichogiou M, Tassios PT, Avlamis A et al (2008) Ongoing epidemic of bla VIM-1-positive Klebsiella pneumoniae in Athens, Greece: a prospective survey. J Antimicrob Chemother 61:59–63

    PubMed  Article  CAS  Google Scholar 

  39. Cagnacci S, Gualco L, Roveta S et al (2008) Bloodstream infections caused by multidrug-resistant Klebsiella pneumoniae producing the carbapenem-hydrolysing VIM-1 metallo-β-lactamase: first Italian outbreak. J Antimicrob Chemother 61:296–300

    PubMed  Article  CAS  Google Scholar 

Download references

Acknowledgements

To the members of the GEMARA and GEIH groups: Emilia Cercenado (Hospital Gregorio Marañon, Madrid), Beatriz Orden (CE Argüelles, CEP Madrid, Hospital Universitario Puerta del Hierro, Madrid), Andrea Mª Gonzalez and Alberto Delgado-Iribarren (Hospital Fundación de Alcorcón, Madrid), Rafael Cantón and M. Isabel Morosini (Hospital Ramon y Cajal, Madrid), Carmen Aspiroz and Blanca Fortuño (Hospital Royo Villanova, Zaragoza), Fe Tubau and Josefina Ayats (Hospital de Bellvitge, Barcelona), F. Javier Castillo and Cristina Seral (Hospital Clínico Universitario Lozano Blesa, Zaragoza), Margarita Salvador and Concepción Segura (Laboratori de Referencia, Barcelona), Cayo Sádaba and Marta Lamata (Fundación Hospital de Calahorra, La Rioja), Ana Granados and Dionisia Fontanals (Hospital Parc Taulí, Barcelona), Frederic Ballester and Oscar Villuenda (Hospital de Sant Joan de Reus, Reus), Frederic Gómez and Rafael Sánchez (Hospital Universitari Joan XXIII, Tarragona), Cristina Pitart and Francesc Marco (Hospital Clínic de Barcelona, Barcelona), Gloria Royo and Montserrat Ruíz (Hospital General Universitari d’Elx, Elx), Mª Luz Núñez and Antonio Altuna Cuesta (Hospital Reina Sofia de Murcia, Murcia), José Luis López and Miguel Salavert (Hospital Universitari La Fe, Valencia), Pilar Marín (Hospital Puerta del Mar, Cadiz), Pilar Teno (Hospital San Pedro de Alcántara, Cáceres), Patricia Iraurgui and Cecilia Martín (Hospital Virgen del Rocío, Sevilla), Gloria Esteban and Begoña Fernández (Complejo hospitalario de Ourense, Ourense), M. Isabel Fernández-Natal (Complejo Asistencial de León, León), Carlos Fuster (Hospital de El Bierzo, León), Fernando García-Garrote and Amparo Coira Nieto (Complejo Hospitalario Xeral-Calde de Lugo, Lugo), Ana Fleites and Marta Lantero (Hospital Universitario Central de Asturias, Oviedo), Andrés Canut (Hospital Santiago Apostol Osakidetza, Servicio Vasco de Salud, Basurto), Estibaliz Ugalde and Carmen Torres (Hospital San Pedro, Logroño), Mª Luz Cordón and Ainara Rodríguez (Hospital de Alto Deba, Mondragón), Mirian Alkorta and Ana María Iturzaeta (Hospital de Zumárraga, Zumárraga), Joxe Mari Manterola (Hospital de Mendaro, Mendaro).

We thank C. Newey for revising the English language in this paper.

Funding

This study was partially supported by the Ministry of Health and Consumer Affairs, Instituto de Salud Carlos III—FEDER, the Spanish Network for Research in Infectious Diseases (REIPI RD06/0008), by a grant from the Fondo de Investigación Sanitaria (PS09/00125) and by AstraZeneca Farmacéutica Spain and Wyeth (now Pfizer) pharmaceutical industries.

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Affiliations

  1. Servei de Microbiologia, Hospital de la Santa Creu i Sant Pau, Institut d’Investigació Biomèdica Sant Pau, Sant Quintí 89, 08041, Barcelona, Spain

    E. Miró & F. Navarro

  2. Service of Microbiology, University Hospital Marqués de Valdecilla—IFIMAV, Santander, Spain

    J. Agüero & L. Martínez-Martínez

  3. Department of Molecular Biology, University of Cantabria, Santander, Spain

    J. Agüero & L. Martínez-Martínez

  4. Servei de Microbiologia, Hospital Vall d’Hebrón, Vall d’Hebron Research Institute, Barcelona, Spain

    M. N. Larrosa & J. J. González-López

  5. Servicio de Microbiología, Complejo Hospitalario Universitario A Coruña, A Coruña, Spain

    A. Fernández & G. Bou

  6. Departamento de Microbiología, Universidad de Sevilla, Sevilla, Spain

    M. C. Conejo & A. Pascual

  7. Antibiotic Laboratory, Bacteriology, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda, Madrid, Spain

    N. Lara, B. Aracil & J. Oteo

  8. Servicio de Microbiología, Hospital Universitario Son Espases, Palma de Mallorca, Spain

    A. Oliver & L. Zamorano

  9. Unidad Clínica de Enfermedades Infecciosas y Microbiología Clínica, Hospital Universitario Virgen Macarena, Sevilla, Spain

    A. Pascual & J. Rodríguez-Baño

  10. Departament de Genètica i Microbiologia, Universitat Autònoma de Barcelona, Barcelona, Spain

    M. N. Larrosa, J. J. González-López & F. Navarro

Authors
  1. E. Miró
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. Agüero
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. N. Larrosa
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. A. Fernández
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. C. Conejo
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. G. Bou
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. J. J. González-López
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. N. Lara
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. L. Martínez-Martínez
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. A. Oliver
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. B. Aracil
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. J. Oteo
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. A. Pascual
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. J. Rodríguez-Baño
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. L. Zamorano
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. F. Navarro
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to F. Navarro.

Electronic supplementary material

Below are the links to the electronic supplementary material.

Figure S1

Prevalence of plasmid-mediated AmpC β-lactamases and carbapenemases in different Spanish Autonomous Communities (PPT 102 kb)

Table S1

(DOC 45 kb)

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Miró, E., Agüero, J., Larrosa, M.N. et al. Prevalence and molecular epidemiology of acquired AmpC β-lactamases and carbapenemases in Enterobacteriaceae isolates from 35 hospitals in Spain. Eur J Clin Microbiol Infect Dis 32, 253–259 (2013). https://doi.org/10.1007/s10096-012-1737-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10096-012-1737-0

Keywords

  • AmpC
  • Great Genetic Diversity
  • Nosocomial Outbreak
  • Enterobacteriaceae Isolate
  • Modify Hodge Test